<DOC>
	<DOCNO>NCT00542217</DOCNO>
	<brief_summary>The purpose trial ass safety , pharmacodynamics , pharmacokinetics escalate dos Imprime PGG™ Injection healthy volunteer .</brief_summary>
	<brief_title>Phase Ia Dose-Escalation Safety , Pharmacodynamic Pharmacokinetic Study Imprime PGG™ Injection</brief_title>
	<detailed_description>The primary objective study evaluate safety tolerability single intravenous dose Imprime PGG versus placebo administer healthy adult subject assess frequency , type , severity treatment emergent adverse event . The secondary objective : 1. determine pharmacodynamics single intravenous dose Imprime PGG administer healthy adult subject assess number subject experience 15 % increase baseline percentage neutrophil prim CR3 ; 2. derive pharmacokinetic profile single intravenous dose Imprime PGG administer healthy adult subject assess plasma concentration Imprime PGG versus time .</detailed_description>
	<criteria>1 . Be age 18 45 year , inclusive 2 . Have body weight 45 125 kg , inclusive , body mass index less equal 30 kg/m2 3 . If female , nonpregnant nonnursing , premenopausal , negative urine pregnancy test confirm prior enrollment practice least two method birth control 4 . Be healthy determine investigator basis medical history , physical examination , electrocardiogram , clinical laboratory test result 5 . Have ability understand requirement study , provide write informed consent , agree abide study restriction return require assessment 6 . Have provide write authorization use disclosure protect health information 1 . Have know hypersensitivity baker 's yeast 2 . Have history tobacco use within 3 month Screening Period 3 . Be know suspected abuser alcohol drug abuse 4 . Have active yeast infection 5 . Have positive hepatitis B , hepatitis C , human immunodeficiency virus test Screening Period 6 . Except otherwise indicate , take prescription medication within 14 day study drug administration Day 0 overthecounter medication , herbal preparation , vitamin within 1 week study drug administration Day 0 ( The follow medication exempt criterion : acetaminophen [ maximum 3 g/day ] , female hormone replacement therapy , oral contraceptive . ) 7 . Have participate investigational drug study within 30 day five halflives ( whichever longer ) Screening Period 8 . Have donate lose unit blood within 30 day Screening Period 9 . Have clinical condition , opinion principal investigator , warrant exclusion study either scientific , procedural , safety perspective</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Healthy Volunteers</keyword>
</DOC>